{"id":"kidney-transplant-maintenance-immunosuppression","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia / new-onset diabetes"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Bone disease / osteoporosis"},{"rate":null,"effect":"Malignancy"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL5314704","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These regimens typically combine multiple immunosuppressive agents (such as calcineurin inhibitors, antiproliferatives, and corticosteroids) that work synergistically to inhibit T-cell activation and proliferation, reducing the immune response against the foreign transplanted kidney. The goal is to achieve sufficient immunosuppression to prevent acute and chronic rejection while minimizing drug toxicity and infection risk.","oneSentence":"Kidney transplant maintenance immunosuppression regimens suppress the recipient's immune system to prevent rejection of the transplanted organ.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:10.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Kidney transplant maintenance immunosuppression to prevent allograft rejection"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06568549","phase":"PHASE4","title":"Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-06-13","conditions":"Kidney Transplantation, Mycophenolate Mofetil","enrollment":350},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT02113891","phase":"PHASE1, PHASE2","title":"Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation","enrollment":""},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT02444429","phase":"PHASE3","title":"3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-09-02","conditions":"Renal Transplantation","enrollment":346},{"nctId":"NCT07045467","phase":"PHASE1","title":"Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-07-01","conditions":"Chronic Kidney Diseases, Renal Transplantation","enrollment":30},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT04953715","phase":"","title":"Microbiome and Immunosuppression: The Mission Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2020-02-12","conditions":"Kidney Transplant Rejection, Kidney Transplant","enrollment":140},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT06676696","phase":"PHASE4","title":"Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-22","conditions":"Renal Failure , Chronic, Graft Failure, Graft Rejection","enrollment":202},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT04225988","phase":"PHASE4","title":"Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-01-09","conditions":"Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT04258423","phase":"PHASE3","title":"Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-12-19","conditions":"Kidney Failure","enrollment":4},{"nctId":"NCT04063865","phase":"PHASE3","title":"Everolimus Monotherapy as Immunosuppression After Liver Transplant","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-05-09","conditions":"Kidney Failure","enrollment":14},{"nctId":"NCT03995901","phase":"PHASE3","title":"A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation","status":"TERMINATED","sponsor":"Talaris Therapeutics Inc.","startDate":"2019-10-25","conditions":"Transplanted Organ Rejection","enrollment":15},{"nctId":"NCT03591380","phase":"PHASE2","title":"CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-14","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT01817504","phase":"NA","title":"Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Renal Transplantation","enrollment":56},{"nctId":"NCT02327403","phase":"PHASE2","title":"Belatacept Conversion in Proteinuric Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-10","conditions":"Proteinuria","enrollment":15},{"nctId":"NCT04431219","phase":"PHASE1, PHASE2","title":"First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients","status":"COMPLETED","sponsor":"Xenothera SAS","startDate":"2019-11-26","conditions":"Kidney Transplant","enrollment":10},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT04420364","phase":"PHASE2, PHASE3","title":"Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-05-03","conditions":"COVID, Kidney Transplant; Complications, Immunosuppression","enrollment":""},{"nctId":"NCT03194321","phase":"PHASE4","title":"Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-09-11","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00807144","phase":"PHASE4","title":"Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2008-12","conditions":"End-stage Renal Failure, Graft Rejection","enrollment":102},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02544113","phase":"PHASE2","title":"A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-12","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT04733131","phase":"","title":"Long-term Outcomes After Conversion to Belatacept","status":"UNKNOWN","sponsor":"Paris Translational Research Center for Organ Transplantation","startDate":"2004-01-01","conditions":"Kidney Transplant Failure and Rejection, Immunosuppression, Graft Loss","enrollment":324},{"nctId":"NCT04114188","phase":"PHASE2","title":"Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2016-12-15","conditions":"Renal Transplant Rejection","enrollment":68},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT01095172","phase":"PHASE4","title":"RituxiMab INDuction in Renal Transplantation","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2010-11","conditions":"Function of Renal Transplant","enrollment":100},{"nctId":"NCT04360031","phase":"","title":"The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2020-02-10","conditions":"Kidney Transplant; Complications, Immunosuppression, Transplant Failure","enrollment":100},{"nctId":"NCT00154193","phase":"PHASE4","title":"Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-06","conditions":"Heart and Lung Transplant","enrollment":190},{"nctId":"NCT01327573","phase":"PHASE1","title":"Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation","status":"COMPLETED","sponsor":"Sanjay Kulkarni","startDate":"2011-03","conditions":"Kidney; Complications, Allograft","enrollment":16},{"nctId":"NCT02040584","phase":"PHASE3","title":"A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-20","conditions":"Liver Transplant","enrollment":217},{"nctId":"NCT01277770","phase":"","title":"Studies of Kidney Transplant Outcome","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-05","conditions":"Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections","enrollment":7500},{"nctId":"NCT00407160","phase":"","title":"A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2004-08","conditions":"Kidney Diseases","enrollment":21},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02134899","phase":"PHASE3","title":"The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10-14","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":3},{"nctId":"NCT01318915","phase":"EARLY_PHASE1","title":"Research Study of ATG and Rituximab in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-25","conditions":"Renal Transplant Recipients","enrollment":10},{"nctId":"NCT00189202","phase":"PHASE2, PHASE3","title":"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2004-08","conditions":"End Stage Renal Disease, Kidney Transplantation","enrollment":49},{"nctId":"NCT02581436","phase":"NA","title":"Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2014-09","conditions":"Disorder Related to Renal Transplantation, Renal Transplant Rejection, Acute Graft Rejection","enrollment":70},{"nctId":"NCT01636466","phase":"PHASE3","title":"The Everolimus-Transplant Exit Strategy Trial (E-TEST)","status":"TERMINATED","sponsor":"Ashtar Chami","startDate":"2013-06","conditions":"Kidney Failure, Chronic","enrollment":1},{"nctId":"NCT01702207","phase":"PHASE4","title":"Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2012-10","conditions":"Immunosuppression, Cardiovascular Diseases, Kidney Transplantation","enrollment":36},{"nctId":"NCT00888628","phase":"PHASE1, PHASE2","title":"Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Diabetes Mellitus, Type I","enrollment":7},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT00716573","phase":"PHASE4","title":"Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-09-16","conditions":"Cardiac Transplantation, Chronic Renal Insufficiency","enrollment":120},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01714440","phase":"","title":"Genomics of Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor","enrollment":1552},{"nctId":"NCT00346151","phase":"PHASE2","title":"Belatacept to Prevent Organ Rejection in Kidney Transplant Patients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12","conditions":"Renal Transplant","enrollment":5},{"nctId":"NCT00284947","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-01","conditions":"Kidney Transplantation, Adverse Effects","enrollment":7},{"nctId":"NCT00240994","phase":"PHASE2","title":"Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":35},{"nctId":"NCT03005236","phase":"PHASE4","title":"AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2017-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00001984","phase":"PHASE2","title":"Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1999-11","conditions":"Graft Rejection, Kidney Disease","enrollment":5},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT02208791","phase":"PHASE4","title":"Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2014-07","conditions":"Kidney Transplantation","enrollment":45},{"nctId":"NCT01169701","phase":"PHASE4","title":"24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Renal Transplant","enrollment":71},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01025817","phase":"PHASE3","title":"Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Kidney Transplant","enrollment":613},{"nctId":"NCT00817206","phase":"PHASE3","title":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Failure","enrollment":326},{"nctId":"NCT02496494","phase":"PHASE4","title":"The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2012-09","conditions":"CYCLOSPORINE/TACROLIMUS","enrollment":50},{"nctId":"NCT01046045","phase":"PHASE4","title":"Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-04","conditions":"Chronic Allograft Dysfunction in Renal Transplantation","enrollment":17},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63},{"nctId":"NCT00133172","phase":"PHASE4","title":"Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2005-07","conditions":"Kidney Transplantation","enrollment":85},{"nctId":"NCT00472082","phase":"PHASE1, PHASE2","title":"Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Emory University","startDate":"2007-05","conditions":"Kidney Transplantation, Chronic Kidney Failure","enrollment":5},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT00311311","phase":"PHASE3","title":"Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Atherosclerosis, Kidney Failure","enrollment":72},{"nctId":"NCT00587158","phase":"NA","title":"Oral Paricalcitol in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary","enrollment":100},{"nctId":"NCT01033500","phase":"NA","title":"Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2010-07","conditions":"Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation","enrollment":""},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00214279","phase":"NA","title":"MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2002-05","conditions":"Renal Transplantation","enrollment":32},{"nctId":"NCT00147381","phase":"PHASE3","title":"Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2004-01","conditions":"Kidney Transplantation","enrollment":197},{"nctId":"NCT00316810","phase":"PHASE3","title":"Simultaneous Pancreas-kidney Transplantation With Campath Protocol","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2006-04","conditions":"Pancreas-Kidney Transplantation","enrollment":30},{"nctId":"NCT00275535","phase":"PHASE4","title":"The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-04","conditions":"Kidney Diseases","enrollment":165},{"nctId":"NCT01455649","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults","status":"UNKNOWN","sponsor":"Deise de Boni Monteiro de Carvalho","startDate":"2011-11","conditions":"Kidney Transplant, Immunosuppression","enrollment":30},{"nctId":"NCT00890253","phase":"PHASE2","title":"Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation","status":"UNKNOWN","sponsor":"Armin Goralczyk","startDate":"2010-01","conditions":"Liver Transplantation, Chronic Renal Insufficiency","enrollment":29},{"nctId":"NCT01276457","phase":"PHASE3","title":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Transplantation Infection","enrollment":223},{"nctId":"NCT00434590","phase":"PHASE4","title":"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-03","conditions":"Kidney Transplantation","enrollment":10},{"nctId":"NCT00912678","phase":"PHASE4","title":"Minimizing Immunosuppression in Old for Old Kidney Transplantation","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2002-03","conditions":"Kidney Transplantation","enrollment":90},{"nctId":"NCT00684372","phase":"NA","title":"BK Viremia After Renal Transplantation","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2007-05","conditions":"Terminal Renal Failure, BK Virus Infection","enrollment":100},{"nctId":"NCT00461825","phase":"PHASE3","title":"Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"1998-07","conditions":"Kidney Transplantation","enrollment":207},{"nctId":"NCT00309270","phase":"PHASE2","title":"Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2003-02","conditions":"Kidney Transplant","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1008,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf"],"phase":"marketed","status":"active","brandName":"Kidney transplant maintenance immunosuppression","genericName":"Kidney transplant maintenance immunosuppression","companyName":"Imperial College Healthcare NHS Trust","companyId":"imperial-college-healthcare-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kidney transplant maintenance immunosuppression regimens suppress the recipient's immune system to prevent rejection of the transplanted organ. Used for Kidney transplant maintenance immunosuppression to prevent allograft rejection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}